Prevention and treatment of hepatic encephalopathy
Сиволап Y. П.
Журнал неврологии и психиатрии им. C.C. Корсакова
Т. 117, Вып. 10, С. 144-147
Опубликовано: 2017
Тип ресурса: Обзор
DOI:10.17116/jnevro2017117101144-147
Аннотация:
Hepatic encephalopathy is a common neuropsychiatric complication of serious liver diseases and serves as a marker for worsening of their course and increasing the risk of death. The principal pathogenesis factors of hepatic encephalopathy is the excessive formation of ammonia and its accumulation by astrocytes. A key role in the prevention and treatment of hepatic encephalopathy is played by drugs that prevent hyperammonemia and promote the removal of ammonia from the body, namely lactulose, rifaximin and L-ornithine-L-aspartate. L-ornithine-L-aspartate has proven clinical effectiveness in the treatment of hepatic encephalopathy, prevents the transformation of minimal hepatic encephalopathy into overt forms, increases the tolerability of psychotropic drugs used in the treatment of alcohol dependence, and improves cognitive functions. © 2017, Media Sphera Publishing Group. All rights reserved.
Ключевые слова:
Alcohol liver disease; Ammonia; Astrocytes; Hepatic encephalopathy; Hyperammonemia; L-ornithine-L-aspartate; Lactulose; Liver cirrhosis; Portosystemic shunting; Rifaximin
lactulose; ornithine aspartate; psychotropic agent; rifaximin; ammonia; dipeptide; lactulose; ornithylaspartate; rifamycin; rifaximin; alcoholism; astrocyte; cognition; drug tolerability; hepatic encephalopathy; human; hyperammonemia; pathogenesis; prophylaxis; Review; complication; drug effects; hepatic encephalopathy; hyperammonemia; metabolism; pathophysiology; Ammonia; Cognition; Dipeptides; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Rifamycins
Язык текста: Русский
ISSN: 2309-4729
Сиволап Y. П.
Sivolap Y. P.
Prevention and treatment of hepatic encephalopathy
Текст визуальный непосредственный
Журнал неврологии и психиатрии им. C.C. Корсакова
Издательство Медиа Сфера
Т. 117, Вып. 10 С. 144-147
2017
Обзор
Alcohol liver disease Ammonia Astrocytes Hepatic encephalopathy Hyperammonemia L-ornithine-L-aspartate Lactulose Liver cirrhosis Portosystemic shunting Rifaximin
lactulose ornithine aspartate psychotropic agent rifaximin ammonia dipeptide lactulose ornithylaspartate rifamycin rifaximin alcoholism astrocyte cognition drug tolerability hepatic encephalopathy human hyperammonemia pathogenesis prophylaxis Review complication drug effects hepatic encephalopathy hyperammonemia metabolism pathophysiology Ammonia Cognition Dipeptides Hepatic Encephalopathy Humans Hyperammonemia Lactulose Rifamycins
Hepatic encephalopathy is a common neuropsychiatric complication of serious liver diseases and serves as a marker for worsening of their course and increasing the risk of death. The principal pathogenesis factors of hepatic encephalopathy is the excessive formation of ammonia and its accumulation by astrocytes. A key role in the prevention and treatment of hepatic encephalopathy is played by drugs that prevent hyperammonemia and promote the removal of ammonia from the body, namely lactulose, rifaximin and L-ornithine-L-aspartate. L-ornithine-L-aspartate has proven clinical effectiveness in the treatment of hepatic encephalopathy, prevents the transformation of minimal hepatic encephalopathy into overt forms, increases the tolerability of psychotropic drugs used in the treatment of alcohol dependence, and improves cognitive functions. © 2017, Media Sphera Publishing Group. All rights reserved.